CTSO Research and Charts

CTSO - CytoSorbents Corp (Healthcare: Medical Devices)

Projected Earnings Date: 2024-08-05 (Delayed quote data 2025-01-06)

Last 1.04	Change ⇑ +0.10 (+0.00%)	Volume 990,913
	Open 1.01	High 1.15	Low 0.98

8EMA (Daily) 0.94	40EMA (Daily) 0.94	50EMA (Daily) 0.95	STO (Daily) 46.128	MACD Hist (Daily) 0.032
8EMA (Weekly) 0.973	40EMA (Weekly) 1.08	50EMA (Weekly) 1.15	STO (Weekly) 35.795	MACD Hist (Weekly) 0.013


Company Profile
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend, K ontrol, and DrugSorb. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.